Note: This story was updated Aug. 6, 2020, to note that ketoconazole is approved to treat Cushing’s in Europe…
Articles by Joana Carvalho, PhD
Estrogen receptor alpha — one of the two main types of protein receptors activated by the female sex hormone…
The last patient has completed the last study visit in the withdrawal phase of the Phase 3 LOGICSÂ clinical…
Genetic variations in the glucocorticoid receptor may explain why some patients with Cushing’s syndrome lose muscle strength, a study…
The oral investigational treatment Recorlev (levoketoconazole) leads to sustained improvements in the control of cortisol among…
Cushing’s syndrome should be suspected in children and adolescents with evident growth delays, and signs of rapid weight gain,…
In real-life clinical practice, Novartis‘ Signifor (pasireotide) completely or nearly normalizes the levels of cortisol in the urine…
Strongbridge Biopharma is preparing the submission of a New Drug Application (NDA) with the U.S. Food and…
Strongbridge Biopharma’s Recorlev (levoketoconazole) alleviates clinical signs and symptoms of Cushing’s syndrome that may…
Strongbridge Biopharma‘s Recorlev (levoketoconazole) continues to show clinically meaningful improvements in the control of cortisol among patients with …